does. It is only its unpredictable failure and difficulty in diagnosing it that presents a clinical problem.
The Coagulation Balance
As indicated schematically in figure 2, blood fluidity is maintained in dynamie equilibrium, which may be shifted either toward /hypocoagulability, resulting in hemorrhage, or toward hypercoagulability, resulting in thrombosis. The nunmerous clotting components involved are depicted in table 1 where they are categorized in the four sequential phases of coagulation in which they function: (1) thromboplastin generation; (2) thrombin fornmation from prothrombin; (3) fibrin deposition; and (4) fibrin dissolution.
Although the conventional anticoagulants are more often than not invoked after a thrombotic episode, their use in prophylaxis is substantial, and is receiving increasing attention. In contrast to these drugs, thrombolytic agents are intended to dissolve clots only after they form. Nobody can argue the validity of this approach, especially when an already existing physiologic mechanism is employed, provided we have safe therapeutic agents, adequate diagnostic tests, adequate comprehension of the thrombolytic mechanism, adequate guides to therapy, understanding of hazards, and antidotes available whenever therapy may get out of hand. Plasminogen synonymous with pr-ofibtwinolysin; plasmin, with fibrinolysin; Ac-globulin, with factor V; SK refers to streptokinase, an entity derived from streptococci, which activates the fibrinolytic system in many species, including man. edge of thrombolysis ? Indeed, is there any close relationship between clotting as such and fibrinolysis? Recent investigations do indeed show a close interrelationship. It is striking for example how fibrinolytic activity evolves as blood clots.1 Also noteworthy is the antithrombotic effect of fibrinogen-fibrin and the products of fibrinolysis.2-8 Also to be mentioned is the antifibrinolysin activity of platelets.9' 10 Space does not permit further elaboration. Suffice it to say that those concerned with thrombolysis, or, speaking as an internist, with "medical thrombectomy," should be familiar with the other coa.gulation phenomena, since they both overlap and profoundly influence one another. Thrombolytic a.gents affect certain clotting constituents, some adversely, leading to possible hemorrhage. When used in combination with the conventional anticoagulants, as has been done, this could conceivably be serious, if not catastrophic. Accordingly, the internist who invokes thrombolytic therapy should recognize that in so doing he may so endanger hemostasis as to replace thrombotic disease with hemostatic failure. Our experience with the orthodox anticoagulants is all too bitter in this regard.
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Figure 2
Scheme depicting dynamic equilibrium of coagulation mecha'nism.
for two thirds of a century, and its historical aspects have been excellently reviewed.' 10 15-19 The active enzyme (fibrinolysin, plasminogen), arising from its inert precursor (profibrinolysin) in any one of several ways, is a protease with a particularly high specificity for the fibrinogen-fibrin system. It also exerts a proteolytic effect on other plasnma proteins, especially on certain other clotting components. 20 One should also bear in mind, moreover, that blood contains other proteolytic enzymes besides fibrinolysin. Thus, thrombin that arises from factor II (prothrombin ) is a highly specific protease that splits fibrinogen, yielding fibrin and fibrinopeptide. Similarly, blood contains tryptases that have proteolytic properties resembling pancreatic trypsin.10 Evidence is presented to show certain similarities as well as differences in the action of these various proteases on clotting factors.
The Shwartzman Reaction, Intravascular Coagulation, and Fibrinolysis
Let us now consider what may happen when fibrinolysis is activated, especially in patients with possible abnormal hypercoagulation in connection with thrombotic disease. Several years ago McKay and Shapiro2' showed that the generalized Shwartznian phenomenon induced in rabbits by bacterial endotoxin, reflected intravascular coagulation that results in bilateral renal cortical necrosis due to fibrin deposition in the small renal vessels. This intravascular coag-ulation, leading to moderate fibrinogenopenia, can be prevented by anticoagulants,22 or it can be prevented, and even reversed, by administration of streptokinase, which activates the fibrinolytic system. 25 Thus, we have in the Shwartzman phenomenon an experimental approach t.o investigation of intravascular clotting and of thrombolysis. In a recent study in our laboratory24 the Shwartzman reaction alone was found to produce some reduction in fibrinogen and platelets (table 2) , as well as marked impairment in thromboplastin generation ( fig. 3 ), the first phase of coagulation. Nevertheless, despite these defects hemostasis was not seriously inmpaired, although some animals succumbed to hemopericardium following ea.rdiae puncture. Similarly, fibrinolytic activation by streptokinase alone did not affect hemostasis in the doses used.24 Plasma fibrinogen remained relatively unchanged despite the fact that clot lysis was markedly accelerated. When streptokinase was given concurrent with the Shwartzman reaction, hbowever, a severe hemorrhagic diathesis resulted with complete afibrinogenemia or marked hypofibrinogenemia.24 Thus, although the defects arising from each namely streptokinase alone or the Shwartzman reaction alone were not sufficient to endanger hemostasis, together they produced profound hemos.tatic failure. It is, thus evident that fibrinolytic activation in a situation where intravascular fibrin deposition is Similar experiments were also made in vitro. The effects were compared with those of trypsin, an enzyme long known to affect coagulation factors,25-27 and studied extensively by us. Moreover, trypsin is still available for thrombolytic therapy28' 29 despite the reported hazards,30' 31 and much has been made of its alleged anti-inflammatory action.32
The simultaneous addition to rabbit plasma of a minute amount of thrombin (0.125 U per ml.) and strept.okinase (Varida.se, 2,500 U per ml.) caused prompt disappearance of assayable fibrinogen, in striking contrast to the effects of the streptokinase alone ( fig. 4 ). 24 This latter mixture, it should be noted, had marked fibrinolytic acetivity, since following recalcification of the streptokinase-containing plasma., the clot dissolved within 2.minutes.
We have thus duplicated in vitro what was observed in vivo, namely, fibrin deposition by thrombin, plus fibrinolytic activation. As a result, afibrinogfenemia or marked hypofibrinogenemia supervened. This is in harmony witb Circulation, Volume XXVI, October 1962 the findings of Sherry and Alkjaersig,10' 16 who earlier emphasized that when clotting simultaneously occurs with fibrinolytic activation, rapid "fibrinolysis" ensues. This was attributed by them to plasmin adsorption onto the clot, where it exerts it.s lytic action. These authors believe that fibrinolysin exhibits little fibrinogenolytic activity compared with fibrinolytic, whereas thrombin is thought to be fibrinogenolytic but not fibrinolytic. Be that as it may, a combination of thrombin and fibrinolysin ca.uses prompt and virtually complete obliteration of the thrombin-fibrinogen interaction.
Sherry and Alkjaersigt0' 10 attribute the relatively low fibrinogenolytic action of fibrinolysin vis-a-vis fibrin, to the antifibrinolysin of plasma; in this way fibrinogen is thought to be preserved. Our observations suggest an alternate explanation, namely, that fibrinolysin promptly attacks the products of the thrombin-fibrinogen interaction (fibrin and fibrin monomers) rather than fibrinogen itself. In so doing, fibrinolysin could in vivo accelerate clotting by releasing absorbed thrombin front the thrombin-fibrinogen-fibrin saline weas used as diluent of barium sulfate adsorbed oxalated plasma and of serum. The latter was derived from normal blood 2 hours after coagulation. Asolectin (Associated Concentrates, Long Island, New York.) provided the phospholipid in the thromboplastii generating mixture. comiplex, thus initiating or accelerating a vicious circle leading to the defibrination characteristic of "fibrinolytic purpura." Such accelerated clotting, or "hypercoagulability" has often been observed early in thrombolytic therapy.33-3 In any event, great caution is indicated whenever thrombin miay be forming, as in thromboenmbolic disease. Fortunately. an antidote is now available in epsilon (e-) aminocaproic acid, a relatively safe drug which inhibits fibrinolytic activation. 36 38 As with vitamin K1 or protamine in reversing the conventional anticoagulants, one can now disengage fromn throiymbolytie therapy with this drug. It is apparently also useful in idiopathic fibrinolytic states.38
Effect of Trypsin and Fibrinolysin on Thrombin-Fibrinogen Interaction*
Since much of our knowledge regarding fibrinolysis depends on our ability to measure fibrinogen, and this in turn upon its clottability by thrombin, it was considered important to study this reaction in imore isolated systems. As evident in figure 5, within 30 seconds after exposure of fibrinogen to trypsin (2.0 U per ml.), its clottabilitv by thrombin was greatly impaired, particularly at fibrinogen coneentrations. below nmixture. Prior exposure of thrombin to plasmin did not affect its clotting ability. Although trypsin, on the other hand, destroys thrombin (8 U of trypsin completely inactivates 1 U of thrombin in 15 minutes), it does not do so sufficiently fast to explain the observations. These data, resembling in vivo and in vitro observations of Fletcher et al., 39 Deutsch and Fisher,40 Beller and Glas, 35 and, as will be seen later, observations on a patient who was treated, raise provocative questions: How is the thrombin-fibrinogen interaction compromised ? Is this true " fibrinogenolysis, " namely, proteolytic destruction of the fibrinogen? If so, how can the fibrinogen be degraded that instantaneously ? Or, do the phenomena reflect competitive blocking involving the substrate, fibrinogen, and the respective protease-trypsin or fibrinolysinvis-a-vis thrombin? And how do the phenomena relate to the incoagulability and apparent fibrinogenopenia in pathologic or induced thrombolytic states? Indeed, as will be seen later, the degree to which fibrinolysin bloeks the clottability of fibrinogen by thrombin may be a valuable guide to thrombolytic therapy. Finally, is this the antithrombin phenomenon Progressive inhibitory effect of human plasmin on clottability of bovine fibrinogen by thrombin. Plasmin-fibrinogen incubation mixture, 0.3 ml., was added a't intervals specified to 0.2 ml. of a soybean-trypsin inhibitor (Worthington) solution. To this combination 0.1 ml. of a thrombin solution was added. Although plasmin and thrombin are not affected by soybean inhibitor (see table 5 ), the latter was included for the purpose of comparison with similalr studies with trypsin, where the inhibitor was employed in order to exclude possible tryptic digestion of thrombin consequent to their admixture. observed by Kowalski and collea.gues,4 5 who attribute it to the proteolytic products obtained from fibrinogen by fibrinolysin? Aside from its ba,sic biologic significance, the findings are clinically important, since the fibrinogen is no longer assayable,j1 or available for hemostatic function.
Effect of Proteases on Clotting Components
Let us now go on to some observations, on the action of proteases on other clotting components. The data help elucidate certain observations in patients under treatment. As shown in table 3, of many proteolytic enzymes studied, only tvwo-trypsin and papain-could convert factor II to thrombin. 42 4 In the presence of trypsin, thrombin evolves rapidly ( fig. 7 ), no other clotting factor is needed, and the reaction is considera,bly enhanced by electrolytes.
Similar studies were made on highly purified factor VII (proconvertin) and factor X (Stuart).44 45 purified factor VII ( fig. 8 ) as well as factor X ( fig. 9 ). Papain and ficin, two other proteases resembling trypsin, also rapidly and almost explosively activate these entities. Of many proteolytic enzymes studied (table 4) , only trypsin, papain, and ficin exhibited the-se activating properties. It should be noted that no thrombin appears. The reaction does not need calcium, and can be prevented by soy bean, or pancreatic, trypsin inhibitor. This suggests that activation is related to specific proteolytic cleavage an arginyl or lysyl peptide bond. Fibrinolysin and thrombin were inert. The other proteases were also either inert or they destroyed the respective clotting factors.
These observations are of more than academic interest. As already mentioned, blood contains trypsin or trypsin-like proteases counterbalanced by plasma antitryptase. Furthermore, trypsin has been used for thrombolytic therapy. From the data presented, its use is deplored: first, it converts factor II to thrombin; secondly, it explosively activates factors VII and X; thirdly, it activa.tes fibri- Trypsin activation of purified bovine factor VII (proconvertin). Material obtained by procedure described earliert(63) and assayed by two methods: (a) 0wreen procedure6'; (b) corrective effect ont the abnormal prothrombin timne of congenital factor V11-deficient blood. 66 nolysin. 45 The net result of trypsin administration would be to induce intravascular coagulation while at the same time triggering the fibrinolytic mechanism. The disastrous consequence of this combination has already been demonstrated. Comparative Actions of Thromboplastin, Trypsin, and Thrombin Of considerable interest is the similarity in the action of tissue thromboplastin with that of trypsin on factors II, VII, and X.47 The addition of thromboplastin to serum rapidly and profoundly inereased the activity of both factors VII and X, the latter more profoundly ( fig. 10 ). Here we see the effect of these fac- tors in the serum of a pregnant patient. This is demonstrable with nongravid sera also ( fig.  11 ), as well as with highly purified material freed from other clotting factors by serum fractionation and starch-gel electrophoresis ( fig. 12 ). Activation with thromboplastin, as with trypsin, is inhibited by trypsin inhibitors. It would therefore appear that the thromboplastic pathway of thrombin formation also involves proteolysis, resembling the action of trypsin and other proteases. We can now appreciate more fully the potentially dreadful consequence of the intravenous liberation of thromboplastic material from extravascular sources, as occurs in pregnancy,48-50 leading to intravascular coagulation and the defibrination syndrome.
It is now opportune to compare fibrinolysin with trypsin, thrombin, and thromboplastin in their effects on factor V (Ae-globulin). Purified human fibrinolysin* rapidly increases factor V activity, followed by rapid decay, depending upon the concentration of fibrinolysin ( fig. 13 ). The des-tructive effect is, in accord with in vivo observations obtained by others in spontaneous51 and induced fibrinolytic states with whole blood and plasma systems 16, 35, [51] [52] [53] [54] [55] [56] and is in sharp contrast to the negative effects of fibrinolysin on factors II, VII, and X, des-cribed earlier. 
INCUBATION TIME-MINUTES

Figure 11
Enhancement in factor X activity of sera by addition of human brain thromboplastin. All the sera except the one designated by the solid squares (fresh serum), were frozen at the same time, stored, subsequently thawed immediately prior to study, diluted 1:20 with physiologic saline, and mixed with an equal part of human brain thromboplastin extract and 0.04 AI calcium chloride. The factor X activities of the undiluted sera just before addition of thromboplastin were 100 per cent for the tormal subjects; 88 per cent (B. Co.), 124 per cent (P. Ca.), and 165 per cent (M. Sp.) for the pregnant sera, respectively. The first values recorded (at "0," incubation time) are those obtained as soon as technically possible after combination of serum, thromboplastin, and Ca++.
It should also be mentioned, in passing, that our findings that fibrinolysin does not destroy factors, II, VII, and X are contrary to the reports of others.53 ' 57 Thrombin similarly aetivates factor V, whereas trypsin, which strongly activates, factors II, VII, and X, is inert on factor V ( fig.  14) . It would also appear that thromboplastin activates factor V, but the possibility has not yet been excluded that this may be due to a trace contaminant of thrombin. Thus, fibrinolysin and thrombin resemble each other in their activating effects on factor V, and in their inertness on factors II, VII, and X as compared with trypsin and papain (table 5 ). Yet in certain of their effects on fibrinogen, these four proteases are remarkably similar.
The activating effects of fibrinolysin and thrombin on factor V deserve additional comment. Mention has already been made of the hypereoagulability observed early in the *Kindly supplied by Dr. Alan Johnson of New York Hospital, New York. Activation of purified factors VII and X by thromboplastin. The fraction was derived from bovine serum by conventional fractionation technics followed by two starch-gel electrophoretic runs.62, 3 Incubation mixture, containing the specified ingredients, was assayed at intervals indica,ted while standing at room temperatures. The values on the ordinate are expressed as activities in per cent. Normal serum contains approximately 100 per cent activity. Inosithin (Associated Concentrates, Woodside, New York) was inert.
course of thrombolytic therapy, and how fibrinolysis might initiate or accelerate a vicious circle by releasing thrombin adsorbed to fibrin or fibrin monomner. We ulow can visualize another mechanism for producing hypercoagulability, namely, activation of factor V by both fibrinolysin and thrombin before the activated factor disappears.
Clinicolaboratory Changes in Thrombolytic Therapy
The untoward acetion of relatively large amounts of fibrinolysis on factor V and fibrinogen is of profound significaniee in thrombolytie therapy, as indicated by some observations on a patient treated for thrombosis of the right retinal artery (table 6) . Two years previously, he became blind in the left eye from similar pathology. Oni February 22, in terms of the factor V activity of plasma. The material was devoid of factors II, VII, and X. The plasmin preparation, kindly supplied by Dr. Alan Johnson of New York Hospital, was derived from purified bovine plasminogen, spontaneously activated in glycerol. In the factor V assay pro-cedure69 the fraction alone, i.e., in the absence of added factor V, exhibited 11 per cent factor V activity. In the experiments, all the combinations of factor V with plasmin showed significanit activation over and above the initial factor V activity (taken at 100 per cent) within 20 seconds following admixture, (including an early obserration of "0,, which is not shown).
1961, he suddenly experienced transient colored scot.omata and blurred vision on the right. When the disturbance recurred the next day and persisted, he was promptly referred for therapy, which was started within a few hours. It should be noted first that relatively large doses of thrombolysin were administered. Secondly, a modest amount of heparin was also given intravenously, not as an anticoagulant, but because heparin enhances fibrinolytic activity in doses that ordinarily do not greatly interfere with clotting.58 The patient also received nicotinic acid orally for its known fibrinolytic potentiation.59 This combination of heparin and nicotinic acid has also been used by others recently in thrombolytic therapy. 58 Thirdly, on the second day of treat- ment the thrombin clotting time was distinctly elevated as compared with that of a normal plasma. This observation, in agreement with what has already been shown regarding interference of the thrombin-fibrinogen interaction by fibrinolysin, indicates that a biologic effect was obtained. This was. substantiated by observations on the prothrombin time. As therapy was continued, the prothrombin time became retarded, most likely due to the effects of fibrinolysin on factor V or fibrinogen. This is indicated by the very low prothrombic activity obtained on whole plasma in contrast to the relatively normal value obtained when the patient 's plasma was admixed with normal plasma rich in factor V and fibrinogen.
Thus, his over-all prothrombic activity was permitted to drop to levels, generally desired with conventional anticoagulant therapy. In this connection it should be emphasized that the heparin was not involved in this result.
Late in the second day, the patient sud-Circulation, Volume XXVI, October 1962 - Table 6 Thrombolytic Therapy and Coagulation-: denly experienced brilliant scotomata, followed by complete clearing of vision, which has been maintained until the present. There were no other reactions,. No claim whatsoever is made that this was a therapeutic triumph. The data are presented merely to extend into the clinic certain obs,ervations made in the laboratory. As such, they suggest guides to therapy. The value of the thrombin clotting time35' 40 and the whole plasma prothrombin time53-55, 60 in this regard has also been mentioned by others.
Summary
The fibrinolytic mechanism, one of the blood protease systems, constitutes a fourth phase of clotting, which contributes to maintenance of coa,gulation in delicate balanee. " Shwartzman "-induced in vivo coagulation, combined with fibrinolysin, produces profound clotting defects with severe hemostatic failure, in contrast to the relative innocuousness of either alone.
The sa.me defects are obtainable in vitro. The thrombin-fibrinogen interaction is blocked, simulating the in vivo " afiibrinogenemia. " These observations are pertinent to thrombo-lytic therapy invoked for conditions where intravascular clotting may be oceurring.
Fibrinogen clottability is also bloeked by trypsin. Apparently, fibrinolysin, thrombin, and trypsin are competitive for fibrinogen. Trypsin, as, well as other proteases, markedly activates, factors II, VII, and X, resembling the action of thromboplastin. In contrast, fibrinolysin and throinbin are inert on these clotting factors, whereas on facetor V' they first acetivate and then destroy it. This explains why factor V depression is. observed in thrombolytic therapy. The activating effect of trypsin oil factors II, VII, and X precludes its use in thrombolytic therapy, and also draws attention to the tryptase-antitrypta.se equilibrium in normal and certain thrombotic s.tates.
The experimental observations help elucidate some clinical and clinicolaboratory findings in acquired "afibrinogenemia" and therapeutically induced "fibrinolytie" states. The retarded thrombin clotting time of -the plasma, and reduction in prothrombic activity attributable to fibrinolytic depression of factor V, may be valuable guides to thrombolytic therapy.
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The most outstanding proof of his strength of character was shown by Galvani during the final year of his life. When an edict of the Cisalpine Republic, created by Napoleon, ordered that all public officials take an oath of allegiance to its constitution, this great patriot refused because he would not subscribe to a formula so contrary to his principles: the oath was atheistic. By refusing to take the oath he lost all his offices at the University and the Institute in April 1798 which reduced him to poverty in his last days. Pietro Giordani wrote that "he neither suffocated the voice of conscience, nor made it subservient to profit and ambition, but accepted poverty, losing without protest those academic offices which were his very bread." His fellow citizens, and specially Giovanni Aldini, appealed to the Government to remedy this injustice, and Galvani was restored to his previous offices as emeritus professor, but the decree was announced when death was about to take him. He died at 61 on December 4, 1798, in the house of his birth to which he had returned to live with his brother following the death of his wife.-Giulio Pupilli. Commentary on the Effect of Electricity on Muscular Motion. BY 
